Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEROPENEM

All injection strengths: not a benefit

Meropenem for Injection · DIN 02536374 · 1g/Vial · Pd for injection solution

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Meropenem for Injection · DIN 02536374 Manufacturer: Jamp Pharma Corporation; listing date 2024-03-28 Health Canada: Marketed since 2024-03-26 · brand MEROPENEM FOR INJECTION · ATC J01DH02 MEROPENEM · form Powder for solution · route Intravenous · ingredients MEROPENEM (MEROPENEM TRIHYDRATE) 1 G/VIAL · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Meropenem for Injection: Formulary list price $47.9900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $47.9900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102515 · Verify on the e-Formulary ↗ (DIN 02536374)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02536374). DIN 02536374: Meropenem for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081207003; group id 18; item number 0024; lccId None; manufacturer id JPC Source form: Pd for Inj Sol; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $47.9900; ministry $47.9900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536374 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102515
Interchangeable products
Meropenem for Injection · DIN 02378795 · $47.9900 Meropenem for Injection · DIN 02493349 · $47.9900 Meropenem for Injection, USP · DIN 02415224 · $47.9900 Merrem · DIN 02218496 · not recorded Taro-Meropenem · DIN 02421526 · $47.9900
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536374
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:07 Carbapenems) and how they are covered
No products matched this class search: “08:12:07”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:12:04 Antifungals, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Meropenem for Injection (meropenem) is indicated for treatment of the following infections when caused by susceptible strains of the designated micro-organisms: Lower Respiratory Tract Community-acquired pneumonia caused by Staphylococcus aureus (methicillin-susceptible strains only), Streptococcus pneumoniae, Escherichia coli and Haemophilus influenzae (including β-lactamase-producing strains). Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible strains only), Escherichia coli, Haemophilus influenzae (non- β-lactamase-producing), Klebsiella pneumoniae and Pseudomonas aeruginosa. Urinary Tract Complicated urinary tract infections caused by Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens. Intra-abdominal Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Clostridium perfringens and Peptostreptococcus species. Gynecologic … https://pdf.hres.ca/dpd_pm/00058292.PDF PM date: October 6, 2020 Source product: MEROPENEM FOR INJECTION; DIN 02378787; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Meropenem for Injection: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026